The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomised women

1984 ◽  
Vol 106 (1) ◽  
pp. 116-120 ◽  
Author(s):  
E. Farish ◽  
C. D. Fletcher ◽  
D. M. Hart ◽  
F. Al. Azzawi ◽  
H. I. Abdalla ◽  
...  
Keyword(s):  
High Density Lipoprotein ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Low Density ◽  
Serum Lipoproteins ◽  
Cholesterol Levels ◽  
Transient Rise

Abstract. Serum lipoproteins were measured over a period of 6 months in 14 oophorectomised women treated with oestrogen implants (50 mg oestradiol-17β) and 17 oophorectomised women treated with oestrogen/testosterone implants (50 mg oestradiol-17β, 100 mg testosterone). Both types of implant caused only minimal changes in lipoprotein metabolism. Low density lipoprotein (LDL) cholesterol decreased with both types of implant and high density lipoprotein (HDL) cholesterol rose with the oestrogen implants. HDL subfractions were also measured. The oestrogen implants caused a transient rise in HDL2 cholesterol levels at 2 months and a slower rise in HDL3 cholesterol. The oestrogen/testosterone implants had no effect on HDL fractions. The results indicate that hormone implants do not cause the profound changes in lipoproteins associated with oral hormone therapy.

Bezafibrate

1983 ◽  
Vol 21 (19) ◽  
pp. 75-76
Keyword(s):  
High Density Lipoprotein ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Significant Risk ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Lipid Lowering ◽  
Low Density ◽  
Cholesterol Levels ◽  
The Uk

Bezafibrate (Bezalip - MCP), an analogue of clofibrate (Atromid-S), has been marketed in the UK for two years. Like clofibrate 1 it lowers both triglyceride and total cholesterol levels in plasma. The reduction is usually in low-density lipoprotein (LDL) cholesterol, whilst high-density lipoprotein (HDL) cholesterol rises. Like other lipid-lowering drugs, it should be used only where appropriate dietary measures have failed and where the hyperlipidaemia poses a significant risk.2

scholarly journals PEMANFAATA N EKSTRAK DAUN WUNGU {Graptophyllum pictum (L.) Griff.} UNTUK PENURUNAN KADAR KOLESTEROL SERUM DARAH MENCIT BETINA YANG DIOVARIEKTOMI

2008 ◽  
Vol 13 (2) ◽  
pp. 97-100
Author(s):  
Listijani Suhargo
Keyword(s):  
High Density Lipoprotein ◽  
Fish Oil ◽  
Blood Serum ◽  
High Density Lipoprotein Cholesterol ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Low Density ◽  
Ovariectomized Mice

The purpose of this research was conducted to evaluate the effects of daun wungu extracts to decrease total cholesterol, LDL (Low Density Lipoprotein) and HDL (High Density Lipoprotein) cholesterol of ovariectomized mice. This research used 24 ovariectomized mice and 8 normal mice. The ovariectomized mice were grouped in 3 groups for K1 (the treatment with aquadest, 0.05 ml), K2 (the treatment with fish oil, 0.05 ml) and P (the treatment with daun wungu extracts, 0.5 mg in 0.05 ml fish oil). All treatments were done for 20 days. At the end of the treatments, the blood (0.5 ml) was taken from cardiac by tuberculin disposable syringe. And then with fotometry, serum total, LDL and HDL cholesterol were measured. The result of this research showed that daun wungu extracts (0.5 mg in 0.05 ml fish oil) could not decrease HDL cholesterol, but it could decrease total and LDL cholesterol of blood serum in ovariectomized mice.

Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia

2001 ◽  
Vol 100 (3) ◽  
pp. 343-355 ◽  
Author(s):  
Agnès BOULLIER ◽  
Nathalie HENNUYER ◽  
Anne TAILLEUX ◽  
Christophe FURMAN ◽  
Nicolas DUVERGER ◽  
...  
Keyword(s):  
High Density Lipoprotein ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Ldl Oxidation ◽  
Low Density ◽  
Human Apolipoprotein ◽  
Cholesterol Levels ◽  
Immunological Markers ◽  
Transgenic Rabbits

High levels of high-density lipoprotein (HDL) cholesterol have been reported to protect against the development of atherosclerosis in humans by increasing reverse cholesterol transport and inhibiting the oxidation of low-density lipoprotein (LDL) due to the paraoxonase content of HDL. The purpose of the present study was to assess if there are any relationships between in vivo increases in serum levels of immunological LDL oxidation markers [autoantibodies against oxidized LDL, autoantibodies against malondialdehyde-modified LDL, LDL immune complexes and anti-cardiolipin autoantibodies], paraoxonase activity and the development of atherosclerosis in control rabbits and in transgenic rabbits expressing human apolipoprotein (apo) A-I. A total of 13 apo A-I transgenic rabbits and 18 non-transgenic littermates were fed on a cholesterol-rich diet (0.4%, w/w) for 14 weeks, and were monitored at weeks 0, 2, 6, 10 and 14. Aortic atherosclerotic lesions were measured at the end of this period. Human apo A-I transgenic rabbits with high HDL cholesterol levels were not protected against the development of atherosclerosis when they were fed on a cholesterol-rich diet which induced dramatic hypercholesterolaemia. Immunological markers of LDL oxidation increased and serum paraoxonase activity decreased similarly in control and transgenic rabbits. In conclusion, the present study demonstrates that high HDL cholesterol levels are ineffective in inhibiting increases in immunological markers of LDL oxidation and the development of atherosclerosis in a mammal with severe hypercholesterolaemia.

Molasses Increases HDL Cholesterol in Rats Research Note

2005 ◽  
Vol 75 (3) ◽  
pp. 211-217 ◽  
Author(s):  
Schlegelmilch ◽  
Brandsch ◽  
Stangl ◽  
Eder
Keyword(s):  
Dry Matter ◽  
Control Diet ◽  
Low Density Lipoprotein ◽  
Dietary Cholesterol ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Cholesterol Concentration ◽  
Low Density ◽  
Serum Lipoproteins ◽  
Cholesterol Levels

Two experiments were conducted to determine whether molasses might exert effects on serum lipoproteins. In experiment 1, 24 rats were divided into two groups and fed diets containing liquid molasses from sugar beet or sucrose (7.71 g of molasses dry matter or sucrose per kg of diet). The second experiment included four groups of rats (n = 12/group) and was conducted in a bifactorial design, with the factors being molasses (non-supplementation vs. supplementation of 77.1 g of molasses dry matter per kg of diet at the expense of sucrose) and dietary cholesterol (0 vs. 5 g/kg diet). In experiment 1, the ratio of low-density lipoprotein (LDL) to high-density lipoprotein (HDL) cholesterol concentration tended to be lower in rats fed the molasses diet than in rats fed the control diet (p < 0.15). In experiment 2, rats fed the molasses diet had higher concentrations of HDL cholesterol (+ 26%) than control rats fed diets without molasses (p < 0.05). This effect was independent of the dietary cholesterol concentration. Concentrations of cholesterol in LDL, very low-density lipoprotein (VLDL), and liver as well as concentrations of triacylglycerols in plasma and liver remained unaffected by molasses in both experiments. In conclusion, the results of this study suggest that supplementation of molasses is effective at raising HDL cholesterol levels in rats.

Effect of a Long-Term Fat-Modified Diet on Serum Lipoprotein Levels of Cholesterol and Triglyceride in Patients on Home Haemodialysis

1981 ◽  
Vol 60 (1) ◽  
pp. 81-86 ◽  
Author(s):  
V. J. Wass ◽  
R. J. Jarrett ◽  
V. Meilton ◽  
M. K. Start ◽  
M. Mattock ◽  
...  
Keyword(s):  
Total Cholesterol ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Low Density ◽  
Home Haemodialysis ◽  
Cholesterol Levels ◽  
Modified Diet

1. Changes in serum total and lipoprotein fraction triglyceride and cholesterol levels were studied in 24 adults on home haemodialysis. Half the patients were randomly allocated to a low cholesterol (mean 200 mg/day), fat-modified diet (mean polyunsaturated/saturated fat ratio of 1.0 with a mean of 43% of the total energy content derived from fat). 2. Before dietary manipulation, triglyceride levels in all lipoprotein fractions were significantly higher (P < 0.02) than in a control group of age and sex matched normal subjects. Total cholesterol, very-low-density-lipoprotein (VLDL) and low-density-lipoprotein (LDL) cholesterol were also significantly raised (P < 0.02), but high-density-lipoprotein (HDL) cholesterol was normal. In the patients on a fat-modified diet triglyceride levels did not alter in any of the lipoprotein fractions. Total cholesterol and LDL cholesterol levels fell significantly into the normal range (P < 0.002 and < 0.001 respectively) but VLDL and HDL cholesterol levels did not change. 3. Hypertriglyceridaemia is the most common lipid abnormality in patients with renal failure and a long-term fat-modified diet is, therefore, of limited therapeutic importance in these patients unless there is a low HDL/LDL cholesterol ratio.

Lipid Levels in Schoolchildren in North East England: Effects of Feeding and Age

1994 ◽  
Vol 31 (3) ◽  
pp. 233-239 ◽  
Author(s):  
K Azad ◽  
S Court ◽  
J M Parkin ◽  
M F Laker ◽  
K G M M Alberti
Keyword(s):  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Low Density ◽  
Lipid Levels ◽  
North East ◽  
Cholesterol Levels ◽  
Log Normal ◽  
Effect Of Feeding

Serum total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, apolipoprotein (apo) A-I and apoB concentrations were estimated and low-density lipoprotein (LDL) cholesterol levels were calculated in 132 children aged 11·4–17·3 years. The effect of feeding was investigated by estimating postprandial values and also by studying the effects of a test meal. The distribution of all data was consistent with Gaussian apart from triglycerides which was log normal. Overall fasting values were [mean (standard deviation; SD)] cholesterol 4·5 (0·8) mmol/L, HDL cholesterol 1·5 (0·4) mmol/L, LDL cholesterol 2·6 (0·8) mmol/L, apoA-I 1·5 (0·3) g/L, apoB 1·0 (0·4) g/L and triglycerides 0·76 (0·38–1·51) mmol/L, the values for triglycerides being mean (95% confidence intervals). Girls had higher triglycerides than boys [0·82 (0·43–1·54) versus 0·70 (0·36–1·33)] and different effects of age on lipids were found, HDL cholesterol being negatively correlated with age in boys ( r= −0·37; P<0·001), but not in girls, and apoA-I being negatively correlated with age in boys ( r= −0·31; P=0·006), but positively correlated with age in girls ( r = 0·32; P = 0·008). Triglycerides rose and HDL cholesterol fell following feeding and inconsistent effects were seen on apoA-I and apoB.

scholarly journals PERBANDINGAN KADAR KOLESTEROL HIGH DENSITY LIPOPROTEIN DARAH PADA PRIA PEROKOK DAN BUKAN PEROKOK

2014 ◽  
Vol 1 (2) ◽  
Author(s):  
Defitson Adolfo Gopdianto
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Sampling Technique ◽  
Hdl Cholesterol ◽  
High Density ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Cholesterol Levels

AbstractBackground: Decrease or increase in blood HDL cholesterol levels affect smokers and nonsmokers. Cigarettes have chemicals that can lead to several health problems such as nicotine. Nicotine resulted in the production of very low density lipoprotein(VLDL) in order to reduce redundant high density lipoprotein cholesterol levels.Method: This type of researchis anobservationalstudyusing across sectional design. Thisstudy populationisstudents ofthe Faculty ofMedicine, University ofSamRatulangi7th semesterof the school year2012/2013with apopulation of150people. Sampling technique inthis research is byusingpurposivesamplingtechniques, smokersand nonsmokersobtainedusing a questionnaire.Result: Determinedthatthere is astatisticallysignificant differencebetweenHDLcholesterol levelsin theblood ofmalesmokersand nonsmokersp=0.49.Cinclusion: There isstatistically significantdifferences inHDLcholesterol levelsin theblood ofmalesmokersand nonsmokers.Keywords: HDLcholesterol levels, smokers, and nonsmokersAbstrakLatar belakang: Penurunan atau peningkatan kadar kolesterol HDL darah berpengaruh pada perokok dan bukan perokok. Rokok memiliki bahan-bahan kimiawi yang dapat mengakibatkan beberapa gangguan kesehatan diantaranya adalah nikotin. Nicotineresulted inthe production ofvery low densitylipoprotein(VLDL) in order toreduceexcessivelevels ofhigh densitylipoproteincholesterol.Metode: Jenis penelitian merupakan penelitian observasional dengan menggunakan rancangan cross sectional.Populasi penelitian ini yaitu mahasiswa Fakultas Kedokteran Universitas Sam Ratulangi semester 7 tahun ajaran 2012/2013 dengan besar populasi berjumlah 150 orang. Teknik pengambilan sampel pada penelitian ini yaitu dengan menggunakan teknik purposive sampling, perokok dan bukan perokok didapatkan dengan menggunakan kuesioner.Hasil:Secara statistik ditetapkan bahwa terdapat perbedaan yang bermakna antara kadar kolesterol HDL darah pada pria perokok dan bukan perokok p=0,49.Kesimpulan: Secara statistik ada perbedaan kadar kolesterol HDL darah pada pria perokok dan bukan perokok.Kata kunci: Kadar kolesterol HDL, perokok, dan bukan perokok.

scholarly journals Trends in Apolipoprotein B, Non-High-Density Lipoprotein Cholesterol, Low-Density Lipoprotein Cholesterol, and Hemoglobin A1C Among US Adults with Diagnosed Diabetes, 2005-2018

2020 ◽  
Author(s):  
X Wang ◽  
Di Zhu ◽  
Yang Du ◽  
Yangbo Sun ◽  
Linda Snetselaar
Keyword(s):  
High Density Lipoprotein ◽  
Apolipoprotein B ◽  
Hemoglobin A1c ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Low Density ◽  
Apo B ◽  
Cholesterol Goal

Abstract Background: The control of blood glucose and athero­genic cholesterol particle concentrations is fundamental for patients with diabetes. The objective of this study was to examine trends in levels of apolipoprotein B (apo B), non-high-density lipoprotein (non-HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and hemoglobin A1c (A1C) and changes in the proportion of patients who achieved their glycemic and lipid goals between 2005 and 2018.Methods: We conducted a serial cross-sectional analysis of the US nationally representative data from the National Health and Nutrition Examination Surveys form 2005 through 2018. Results: In total, 5536 adults aged 20 years or older with diabetes were included (weighted mean age, 60.2 years; female, 50.1%). Among all adults with diabetes, the age-adjusted mean apo B levels did not decrease significantly from 2005 to 2016 (P =0.077). The age-adjusted mean non-HDL cholesterol levels reduced significantly (P =0.004) from 2005 to 2018. In 2017-2018, 55.3% of patients achieved the A1C goal of <7% and 43.8% achieved the non-HDL cholesterol goal of <130 mg/dl. In 2015-2016, 47.3% achieved the apo B goal of <90 mg/dL, 57.2% achieved the LDL cholesterol goal of <100 mg/dl, while 30.6% achieved all four glycemic and lipid goals. The success rates for achieving the goals of apo B, non-HDL cholesterol, and LDL cholesterol were higher in older compared with younger subjects, while white patients exhibited better glycemic control than Mexican Americans and non-Hispanic black patients.Conclusion: Among adults with diabetes, there was a significant reduction in non-HDL cholesterol level while there was no change in levels of apo B, LDL cholesterol or A1C over the past decade. Nevertheless, large percentages of adults with diabetes continue to have higher levels of apo B, non-HDL cholesterol, LDL cholesterol, and A1C.

scholarly journals Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity

2011 ◽  
Vol 96 (10) ◽  
pp. E1568-E1576 ◽  
Author(s):  
Esther M. M. Ooi ◽  
Gerald F. Watts ◽  
Dennis L. Sprecher ◽  
Dick C. Chan ◽  
P. Hugh R. Barrett
Keyword(s):  
High Density Lipoprotein ◽  
Central Obesity ◽  
Low Density Lipoprotein ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Peroxisome Proliferator ◽  
Low Density ◽  
Peroxisome Proliferator Activated Receptor ◽  
Plasma Triglycerides

Abstract Context: Dyslipidemia increases the risk of cardiovascular disease in obesity. Peroxisome proliferator-activated receptor (PPAR)-δ agonists decrease plasma triglycerides and increase high-density lipoprotein (HDL)-cholesterol in humans. Objective: The aim of the study was to examine the effect of GW501516, a PPAR-δ agonist, on lipoprotein metabolism. Design, Setting, and Intervention: We conducted a randomized, double-blind, crossover trial of 6-wk intervention periods with placebo or GW501516 (2.5 mg/d), with 2-wk placebo washout between treatment periods. Participants: We recruited 13 dyslipidemic men with central obesity from the general community. Main Outcome Measures: We measured the kinetics of very low-density lipoprotein (VLDL)-, intermediate-density lipoprotein-, and low-density lipoprotein (LDL)-apolipoprotein (apo) B-100, plasma apoC-III, and high-density lipoprotein (HDL) particles (LpA-I and LpA-I:A-II). Results: GW501516 decreased plasma triglycerides, fatty acid, apoB-100, and apoB-48 concentrations. GW501516 decreased the concentrations of VLDL-apoB by increasing its fractional catabolism and of apoC-III by decreasing its production rate (P &lt; 0.05). GW501516 reduced VLDL-to-LDL conversion and LDL-apoB production. GW501516 increased HDL-cholesterol, apoA-II, and LpA-I:A-II concentrations by increasing apoA-II and LpA-I:A-II production (P &lt; 0.05). GW501516 decreased cholesteryl ester transfer protein activity, and this was paralleled by falls in the triglyceride content of VLDL, LDL, and HDL and the cholesterol content of VLDL and LDL. Conclusions: GW501516 increased the hepatic removal of VLDL particles, which might have resulted from decreased apoC-III concentration. GW501516 increased apoA-II production, resulting in an increased concentration of LpA-I:A-II particles. This study elucidates the mechanism of action of this PPAR-δ agonist on lipoprotein metabolism and supports its potential use in treating dyslipidemia in obesity.

Sign in / Sign up

Export Citation Format

Share Document